MedinCell announces the resume of listing of its shares on Euronext Paris as of the opening of the stock exchange tomorrow
January 7, 2021
Previous PostTeva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
Next PostCovid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin
